Levetiracetam low-dose - AgeneBio

Drug Profile

Levetiracetam low-dose - AgeneBio

Alternative Names: AGB-101; Low-dose levetiracetam - AgeneBio

Latest Information Update: 31 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Johns Hopkins University
  • Developer AgeneBio; Johns Hopkins University
  • Class Acetamides; Antidementias; Antiepileptic drugs; Neuroprotectants; Pyrrolidinones; Small molecules
  • Mechanism of Action SV2A protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Mild cognitive impairment

Most Recent Events

  • 19 Sep 2017 AgeneBio plans the phase III HOPE4MCI trial for Mild cognitive impairment due to Alzheimer's disease in USA in the first quarter of 2018
  • 31 Mar 2017 AgeneBio's low-dose Levetiracetam is still at phase II development stage for Mild cognitive impairment in USA (PO)
  • 10 Jan 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top